[ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The EML4-ALK fusion protein drives a subset of non-small cell lung cancer (NSCLC).
• Targeted therapies like tyrosine kinase inhibitors (TKIs) show efficacy but require accurate EML4-ALK detection.
• Current diagnostic methods, such as Fluorescence In Situ Hybridization (FISH), are resource-intensive.

Purpose of the Study:

• To provide consensus recommendations for testing strategies to identify EML4-ALK translocations in NSCLC.
• To evaluate the role of immunohistochemistry (IHC) as a screening tool for EML4-ALK.
• To guide the sequence and quality of diagnostic tests for optimal patient selection.

Main Methods:

• Literature review and analysis of current diagnostic techniques for EML4-ALK.
• Evaluation of FISH and IHC methodologies for sensitivity, specificity, and resource utilization.
• Development of a consensus-based testing algorithm.

Main Results:

• FISH is an established but resource-demanding method for confirming EML4-ALK.
• Immunohistochemistry (IHC) shows potential as an efficient and accessible method for screening EML4-ALK translocations.
• A sequential testing approach, potentially starting with IHC, is recommended.

Conclusions:

• Accurate identification of EML4-ALK translocations is essential for guiding TKI therapy in NSCLC.
• IHC presents a valuable tool for initial screening, potentially improving accessibility and efficiency.
• Standardized recommendations for diagnostic pathways are needed to ensure timely and appropriate patient management.